

# Study shows low rate of late lumen loss with bioresorbable DESolve device

22 May 2013

---

The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today.

DESolve (Elixir Medical Corporation) is the first bioresorbable PLLA-based [polymer scaffold](#) that releases novolimus, a major [metabolite](#) of [sirolimus](#). "The degradation time is about one year," explained the lead study author Alexandre Abizaid, Director of Interventional Cardiology at Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. He added, "One of the most attractive features, which we don't see with most bioresorbable scaffolds, is that this device shows significant increase in vessel [scaffold](#) and luminal area at six months."

The DESolve Nx trial treated target lesions in 126 [patients](#) with single de novo coronary artery lesions with the DESolve device. Results showed the primary endpoint of in-stent late lumen loss was 0.21mm (+0.34) at six months. Major adverse [cardiac events](#) occurred in 3.25% of patients, including one [cardiac death](#). Acute recoil occurred in 6.6% of patients at six months.

Stents and vessels were assessed by IVUS in a subset of 40 patients. "There was a clearly significant increase in vessel area," Abizaid reported. Mean vessel area increased by 16.8% at six months (p

APA citation: Study shows low rate of late lumen loss with bioresorbable DESolve device (2013, May 22) retrieved 18 August 2022 from <https://medicalxpress.com/news/2013-05-late-lumen-loss-bioresorbable-desolve.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*